Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.

Georg SemmlerSarah WernlySebastian BachmayerIsabella LeitnerBernhard WernlyMatthias EggerLena SchwenohaLeonora DatzLorenz BalcarMarie SemmlerFelix StickelDavid NiederseerElmar AignerChristian Datz

Published in: The Journal of clinical endocrinology and metabolism (2021)

Presence of MAFLD does not increase mortality in a cohort of individuals aged 45 to 80 years.

Keyphrases

cardiovascular events
risk factors
oxidative stress
coronary artery disease
fatty acid